New York, January 15, 2019—Creative Biolabs, a customized IVD antibody services provider, now offers Cancer IVD Antibody Development Services for the diagnosis and prognosis of breast cancers and lung cancers by cancer biomarkers.
Cancer results from mutations that inhibit oncogene and tumor suppressor gene function, leading to uncontrollable cell growth. It’s much difficult to treat cancer cells that spread from one part of the body to another due to metastasis. Therefore, in vitro diagnostic (IVD) antibodies are developed to track and treat the corresponding symptoms of the cancer type.
For the breast cancer, the most common invasive cancer in women as well as the second main cause of cancer death, there are a number of new breast cancer biomarkers that have been proposed for routine use in the management of breast cancer patients including ER-β, androgen receptor (AR) and Ki-67. For the lung cancer, of which the death rate exceeds that of colon, breast and pancreatic cancers combined, multiple cancer biomarkers are available for the treatment, such as CYFRA 21-1, EGFR, FAM83B, CR-1, IDH1, ALK gene, PD-L1, NSE. Scientists in Creative Biolabs can assist clients in the research of early diagnosis and prognosis analysis of lung cancer and provide new insights into clinical heterogeneity and disease emergencies
A scientist engaged in Creative Biolabs said, “Backed up by our powerful platform, we are fully equipped to provide a wide range of highly sensitive and specific diagnostic markers and antibodies development services that can be rapidly commercialized. We are dedicated to becoming an incontestable global leader in diagnostic and management of cancer. In addition to the breast cancer and lung cancer biomarkers, we also offer customized solutions to our clients with the purpose of satisfying every specific requirement.”
About Creative Biolabs
Creative Biolabs is one of the few companies who can offer integrated drug discovery services for clients all over the world. Talented and well-trained scientists are working closely with each other to realize the goal of our customers. To discover and develop the qualified medicines of tomorrow, scientists in Creative Biolabs are concentrating on every important aspect of the industry, especially for the drug discovery pipeline. Services range from target identification and validation, hit identification, hit to lead, lead optimization to the investigational new drug (IND), and are subdivided into numerous details. Creative Biolabs is able to undertake the entire discovery pipeline and also pleased to offer specific service based on clients’ requirements.
Media ContactCompany Name: Creative BiolabsContact Person: Bella SmithEmail: Send EmailPhone: 1-631-619-7922Address:45-1 Ramsey Road City: ShirleyState: New YorkCountry: United StatesWebsite: https://www.creative-biolabs.com/drug-discovery/diagnostics
